^
    almost2years
    Two detection methods of clinical KRAS G12C mutation detection for companion diagnostics (AACR 2023)
    The FDA approved sotorasib, a KRAS G12C inhibitor, for targeted treatment of patients with KRAS G12C-mutated locally or metastatic non-small cell lung cancer (NSCLC)...Our methods are especially valuable for labs that appreciate simple, economical, yet sensitive companion diagnostics assays for KRAS G12C mutation. QClamp® assays can be easily adapted to detect other single gene mutations with high sensitivity for companion diagnostics use or other mutation detection applications.
    Clinical • Companion diagnostic
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    QClamp® KRAS Mutation Detection Test
    |
    Lumakras (sotorasib)
    2years
    The ColoScape Test: A Novel QClamp XNA TechnologyBased Assay to Detect Colorectal Cancer Associated Mutations and Methylations in Plasma Cell-Free DNA (AMP 2022)
    The ColoScape test utilizing the XNA-based technology provides high sensitivity and high specificity to CRC and advanced adenomas with a great potential to be used as an early screening test.
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • PIK3CA mutation
    |
    ColoScape™ Colorectal Cancer Mutation Detection Test • QClamp® BRAF Mutation Detection Test • QClamp® KRAS Mutation Detection Test • QClamp® NRAS Mutation Detection Kit • QClamp® PIK3CA Mutation Detection Test
    almost3years
    Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR. (PubMed, Pharmazie)
    Most mutations occurred at APC876. The four genes' panel detected by XNA-based PCR technique might be suited to efficiently and micro-invasively detect genetic alterations in cfDNA of patients with precancerous colorectal lesions.
    Journal • Circulating tumor DNA
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    KRAS mutation • BRAF mutation • APC mutation • CTNNB1 mutation
    |
    QClamp® BRAF Mutation Detection Test • QClamp® KRAS Mutation Detection Test